A detailed history of Acadian Asset Management LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 56,445 shares of CHRS stock, worth $43,462. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,445
Holding current value
$43,462
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.99 - $1.8 $55,880 - $101,601
56,445 New
56,445 $58,000
Q4 2023

Feb 13, 2024

BUY
$1.59 - $3.85 $941,648 - $2.28 Million
592,232 New
592,232 $1.97 Million
Q2 2022

Aug 09, 2022

BUY
$5.86 - $13.23 $33,519 - $75,675
5,720 New
5,720 $41,000
Q3 2020

Nov 09, 2020

SELL
$17.41 - $19.89 $1.52 Million - $1.74 Million
-87,391 Closed
0 $0
Q2 2020

Aug 12, 2020

SELL
$14.43 - $19.16 $1.54 Million - $2.05 Million
-107,066 Reduced 55.06%
87,391 $1.56 Million
Q1 2020

May 11, 2020

BUY
$11.67 - $22.53 $2.27 Million - $4.38 Million
194,457 New
194,457 $3.15 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $59.8M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.